Treat-And-Extend Versus Pro Re Nata Regimen of Intravitreal Conbercept Injection for Neovascular Age-Related Macular Degeneration: Results from COCOA, a Prospective, Open-Label, Multicenter, Randomized Phase IV Clinical Trial.

IF 1.9 4区 医学 Q2 OPHTHALMOLOGY
Yaoyao Sun, Wenfang Zhang, Bojie Hu, Bin Sun, Tonghe Zhang, Suqin Yu, Gongqiang Yuan, Rongping Dai, Ke Fan, Lifei Wang, Pei Cheng, Gang An, Liangbao An, Fang Wang, Weiqi Chen, Jie Zhang, Xiyuan Zhou, Feng Wang, Jian Ye, Xionggao Huang, Xiaoyan Peng, Jun Li, Miaoqin Wu, Guangming Wan, Jingxiang Zhong, Shaoping Ha, Xiao Ke, Jianhong Liang, Huijun Qi, Hong Yin, Tong Qian, Jinfeng Qu, Xuan Shi, Jing Hou, Heng Miao, Yuou Yao, Enzhong Jin, Xun Deng, Jian Zhang, Xiaoqing Shi, Jun Liu, Jie Ma, Jia Liu, Ye Tao, Bin Liu, Xiaoxin Li, Mingwei Zhao
{"title":"Treat-And-Extend Versus Pro Re Nata Regimen of Intravitreal Conbercept Injection for Neovascular Age-Related Macular Degeneration: Results from COCOA, a Prospective, Open-Label, Multicenter, Randomized Phase IV Clinical Trial.","authors":"Yaoyao Sun, Wenfang Zhang, Bojie Hu, Bin Sun, Tonghe Zhang, Suqin Yu, Gongqiang Yuan, Rongping Dai, Ke Fan, Lifei Wang, Pei Cheng, Gang An, Liangbao An, Fang Wang, Weiqi Chen, Jie Zhang, Xiyuan Zhou, Feng Wang, Jian Ye, Xionggao Huang, Xiaoyan Peng, Jun Li, Miaoqin Wu, Guangming Wan, Jingxiang Zhong, Shaoping Ha, Xiao Ke, Jianhong Liang, Huijun Qi, Hong Yin, Tong Qian, Jinfeng Qu, Xuan Shi, Jing Hou, Heng Miao, Yuou Yao, Enzhong Jin, Xun Deng, Jian Zhang, Xiaoqing Shi, Jun Liu, Jie Ma, Jia Liu, Ye Tao, Bin Liu, Xiaoxin Li, Mingwei Zhao","doi":"10.1080/08820538.2025.2467853","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate and contrast the effectiveness and safety of two conbercept treatment protocols-a three-dose treat-and-extend (3+T&E) regimen and a three-dose pro re nata (3+PRN) regimen-in Chinese patients diagnosed with neovascular age-related macular degeneration (nAMD).</p><p><strong>Methods: </strong>Eligible patients, who had not undergone anti-VEGF intraocular injections within 3 months prior to enrollment, were randomly assigned to either the 3+T&E or 3+PRN regimen. The 3+T&E group received at least three monthly injections, with subsequent visit intervals extended based on disease activity assessment. The primary endpoint was the mean change in best-corrected visual acuity (BCVA) from baseline to week 48, using a predefined noninferiority threshold.</p><p><strong>Results: </strong>Among 501 participants (249 in 3+T&E, 252 in 3+PRN), approximately half had prior anti-VEGF treatment. At 48 weeks, both regimens showed significant BCVA improvements (+9.9 for 3+PRN, +8.6 for 3+T&E; <i>p</i> = .208), with comparable rates of ≥15-letter gains (32.12% for 3+PRN, 30.77% for 3+T&E; <i>p</i> = .827). The 3+PRN group received fewer injections (mean 6.4 vs. 6.9 in 3+T&E; <i>p</i> = .028) but had shorter intervals between injections (6.93 weeks vs. 7.46 weeks in 3+T&E; <i>p</i> = .010). Drug-related adverse events occurred in 5% of patients, with ocular events evenly distributed and minimal cardiovascular events reported.</p><p><strong>Conclusion: </strong>Both 3+T&E and 3+PRN conbercept regimens effectively improved visual and anatomical outcomes in Chinese nAMD patients. The 3+T&E regimen was noninferior to 3+PRN in improving BCVA from baseline to week 48. The 3+T&E regimen enabled longer injection intervals while 3+PRN regimen with less injections is more cost-effective while maintaining a comparable safety profile. Treatment plan tailored to an individual patient's situation appears necessary.</p>","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-7"},"PeriodicalIF":1.9000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08820538.2025.2467853","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To evaluate and contrast the effectiveness and safety of two conbercept treatment protocols-a three-dose treat-and-extend (3+T&E) regimen and a three-dose pro re nata (3+PRN) regimen-in Chinese patients diagnosed with neovascular age-related macular degeneration (nAMD).

Methods: Eligible patients, who had not undergone anti-VEGF intraocular injections within 3 months prior to enrollment, were randomly assigned to either the 3+T&E or 3+PRN regimen. The 3+T&E group received at least three monthly injections, with subsequent visit intervals extended based on disease activity assessment. The primary endpoint was the mean change in best-corrected visual acuity (BCVA) from baseline to week 48, using a predefined noninferiority threshold.

Results: Among 501 participants (249 in 3+T&E, 252 in 3+PRN), approximately half had prior anti-VEGF treatment. At 48 weeks, both regimens showed significant BCVA improvements (+9.9 for 3+PRN, +8.6 for 3+T&E; p = .208), with comparable rates of ≥15-letter gains (32.12% for 3+PRN, 30.77% for 3+T&E; p = .827). The 3+PRN group received fewer injections (mean 6.4 vs. 6.9 in 3+T&E; p = .028) but had shorter intervals between injections (6.93 weeks vs. 7.46 weeks in 3+T&E; p = .010). Drug-related adverse events occurred in 5% of patients, with ocular events evenly distributed and minimal cardiovascular events reported.

Conclusion: Both 3+T&E and 3+PRN conbercept regimens effectively improved visual and anatomical outcomes in Chinese nAMD patients. The 3+T&E regimen was noninferior to 3+PRN in improving BCVA from baseline to week 48. The 3+T&E regimen enabled longer injection intervals while 3+PRN regimen with less injections is more cost-effective while maintaining a comparable safety profile. Treatment plan tailored to an individual patient's situation appears necessary.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Seminars in Ophthalmology
Seminars in Ophthalmology OPHTHALMOLOGY-
CiteScore
3.20
自引率
0.00%
发文量
80
审稿时长
>12 weeks
期刊介绍: Seminars in Ophthalmology offers current, clinically oriented reviews on the diagnosis and treatment of ophthalmic disorders. Each issue focuses on a single topic, with a primary emphasis on appropriate surgical techniques.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信